PetVivo (PETV) Investor update summary

Company overview and strategy

• Focuses on innovative medical devices and therapeutics for companion animals, leveraging technology initially developed for humans and funded by NIH and Department of Defense.

• Operates through four subsidiaries: PetVivo.ai (veterinary innovation and pet owner engagement), PetVivo Animal Health (product commercialization), Gel-Del Technologies (manufacturing), and a partnership with PiezoBio for advanced nanofiber technology.

• Achieved human medical device manufacturing certifications (ISO 5, 7, 8), exceeding veterinary industry standards.

Product innovation and clinical feedback

• Spryng and PrecisePRP are positioned as multimodal solutions for osteoarthritis, providing alternatives to pharmaceuticals and surgery.

• Spryng mimics natural joint tissue, improves lubrication, and serves as a scaffold for healthier joint environments, supporting both immediate and long-term mobility.

• Veterinarians report positive outcomes, especially for pets where surgery is not feasible, and use Spryng both as a treatment and preventive measure.

• Strong feedback from diverse veterinary specialists highlights improved mobility and quality of life for pets.

Market trends and commercial landscape

• Industry trends show a shift toward reducing pharmaceutical use in favor of longer-term, less invasive solutions.

• Insurance companies are recognizing the cost-saving potential of products like Spryng, with committees evaluating advanced technologies for coverage.

• Increasing pet insurance adoption and earlier enrollment are expected to drive demand for preventive joint health solutions.